182 related articles for article (PubMed ID: 35280728)
1. Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives.
Musacchio L; Cicala CM; Salutari V; Camarda F; Carbone MV; Ghizzoni V; Giudice E; Nero C; Perri MT; Ricci C; Tronconi F; Scambia G; Lorusso D
Front Oncol; 2022; 12():831612. PubMed ID: 35280728
[TBL] [Abstract][Full Text] [Related]
2. Exceptional response to lurbinectedin and irinotecan in
Cortesi L; Venturelli M; Barbieri E; Baldessari C; Bardasi C; Coccia E; Baglio F; Rimini M; Greco S; Napolitano M; Pipitone S; Dominici M
Ther Adv Chronic Dis; 2022; 13():20406223211063023. PubMed ID: 35070248
[TBL] [Abstract][Full Text] [Related]
3. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.
Vidal A; Muñoz C; Guillén MJ; Moretó J; Puertas S; Martínez-Iniesta M; Figueras A; Padullés L; García-Rodriguez FJ; Berdiel-Acer M; Pujana MA; Salazar R; Gil-Martin M; Martí L; Ponce J; Molleví DG; Capella G; Condom E; Viñals F; Huertas D; Cuevas C; Esteller M; Avilés P; Villanueva A
Clin Cancer Res; 2012 Oct; 18(19):5399-411. PubMed ID: 22896654
[TBL] [Abstract][Full Text] [Related]
4. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
Patel S; Petty WJ; Sands JM
Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
[TBL] [Abstract][Full Text] [Related]
5. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gaillard S; Oaknin A; Ray-Coquard I; Vergote I; Scambia G; Colombo N; Fernandez C; Alfaro V; Kahatt C; Nieto A; Zeaiter A; Aracil M; Vidal L; Pardo-Burdalo B; Papai Z; Kristeleit R; O'Malley DM; Benjamin I; Pautier P; Lorusso D
Gynecol Oncol; 2021 Nov; 163(2):237-245. PubMed ID: 34521554
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma.
Gadducci A; Cosio S
Front Oncol; 2022; 12():914342. PubMed ID: 36408147
[TBL] [Abstract][Full Text] [Related]
7. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
8. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C; Bello E; Liguori M; Craparotta I; Mannarino L; Paracchini L; Beltrame L; Marchini S; Galmarini CM; Mantovani A; Frapolli R; Allavena P; D'Incalci M
Br J Cancer; 2017 Aug; 117(5):628-638. PubMed ID: 28683469
[TBL] [Abstract][Full Text] [Related]
9. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
11. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
Poveda A; Del Campo JM; Ray-Coquard I; Alexandre J; Provansal M; Guerra Alía EM; Casado A; Gonzalez-Martin A; Fernández C; Rodriguez I; Soto A; Kahatt C; Fernández Teruel C; Galmarini CM; Pérez de la Haza A; Bohan P; Berton-Rigaud D
Ann Oncol; 2017 Jun; 28(6):1280-1287. PubMed ID: 28368437
[TBL] [Abstract][Full Text] [Related]
13. Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.
Yokoi E; Mabuchi S; Shimura K; Komura N; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Invest New Drugs; 2019 Oct; 37(5):818-827. PubMed ID: 30374654
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma.
Anobile DP; Bironzo P; Picca F; Lingua MF; Morena D; Righi L; Napoli F; Papotti MG; Pittaro A; Di Nicolantonio F; Gigliotti C; Bussolino F; Comunanza V; Guerrera F; Sandri A; Leo F; Libener R; Aviles P; Novello S; Taulli R; Scagliotti GV; Riganti C
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34066159
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
[TBL] [Abstract][Full Text] [Related]
16. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma.
Pernice T; Bishop AG; Guillen MJ; Cuevas C; Aviles P
J Pharm Biomed Anal; 2016 May; 123():37-41. PubMed ID: 26871278
[TBL] [Abstract][Full Text] [Related]
17. Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.
Santamaría Nuñez G; Robles CM; Giraudon C; Martínez-Leal JF; Compe E; Coin F; Aviles P; Galmarini CM; Egly JM
Mol Cancer Ther; 2016 Oct; 15(10):2399-2412. PubMed ID: 27630271
[TBL] [Abstract][Full Text] [Related]
18. Lurbinectedin in small cell lung cancer.
Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
Front Oncol; 2022; 12():932105. PubMed ID: 36110944
[TBL] [Abstract][Full Text] [Related]
19. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
